NCT01154114View on ClinicalTrials.gov

Study to Evaluate Darapladib in Moderately Hepatically Impaired Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

July 1, 2010

Primary Completion Date

October 15, 2010

Study Completion Date

October 15, 2010

Conditions

Atherosclerosis

Interventions

DRUG

darapladib

darapladib 40 mg oral dose

Trial Locations (2)

32809

GSK Investigational Site, Orlando

33143

GSK Investigational Site, Miami

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT01154114 - Study to Evaluate Darapladib in Moderately Hepatically Impaired Subjects | Biotech Hunter | Biotech Hunter